The major drawback of current anti-angiogenic therapies is the hypoxia-induced drug resistance, which stimulates cancer cells to develop aggressive and immunosuppressive phenotypes, mainly via activation of HIF-1 pathways [43, 44]. This evidence concerns the gene HIF1A and cancer.